SCHEMBL22386375

SCHEMBL22386375

O=Nc1ccc(/C=C2\S/C(=N\c3ccccc3)N(Cc3ccco3)C2=O)cc1

nearest known ligand 0.73

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 3/20 0.73
▸ LMNA P02545 2/20 0.61
▸ SMN1; SMN2 Q16637 2/20 0.61
▸ MEN1 O00255 1/20 0.61
▸ FNTA P49354 1/20 0.61
▸ FNTB P49356 1/20 0.61
▸ KMT2A Q03164 1/20 0.61
▸ NPSR1 Q6W5P4 1/20 0.61
▸ CA9 Q16790 10/20 0.56
▸ PTPN1 P18031 3/20 0.53
▸ ACP1 P24666 3/20 0.53
▸ CA2 P00918 3/20 0.51
▸ HPGD P15428 1/20 0.51
▸ CRHBP P24387 1/20 0.51
▸ CRHR2 Q13324 1/20 0.51
▸ MGAM O43451 1/20 0.51
▸ CA12 O43570 1/20 0.51
▸ CA1 P00915 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17302245 0.93 FAAH (0.76) FAAHLMNASMN1; SMN2MEN1FNTA
SCHEMBL17295376 0.93 FAAH (0.76) FAAHLMNASMN1; SMN2MEN1FNTA
SCHEMBL17309449 0.90 FAAH (0.76) FAAHLMNASMN1; SMN2MEN1FNTA
SCHEMBL19481515 0.90 FAAH (0.76) FAAHLMNASMN1; SMN2MEN1FNTA
SCHEMBL17302247 0.88 FAAH (0.70) FAAHLMNASMN1; SMN2MEN1FNTA
SCHEMBL17295283 0.88 FAAH (0.70) FAAHLMNASMN1; SMN2MEN1FNTA
SCHEMBL17302232 0.87 CA9 (0.69) FAAHLMNASMN1; SMN2MEN1FNTA
SCHEMBL17309395 0.84 FAAH (1.00) FAAHLMNASMN1; SMN2MEN1FNTA
SCHEMBL17295572 0.81 FAAH (0.64) FAAHLMNASMN1; SMN2MEN1FNTA
SCHEMBL17295570 0.81 FAAH (0.64) FAAHLMNASMN1; SMN2MEN1FNTA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3148541-B1 THIAZOLIDINONES AS CELLULAR ANANDAMIDE UPTAKE INHIBITORS AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL DISORDERS AND INFLAMMATION, IN PARTICULAR NEUROINFLAMMATION UNIV BERN (CH) 2020-09-02 — — EP disclosed
Send feedback